Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 14/20 | 0.36 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883248 | 1.00 | GYS1 (0.36) | GYS1RXRANR1H2NR1H3FPR2 | |
| SCHEMBL1879564 | 1.00 | GYS1 (0.36) | GYS1RXRANR1H2NR1H3FPR2 | |
| SCHEMBL1876952 | 0.95 | GYS1 (0.37) | GYS1RXRANR1H2NR1H3FPR2 | |
| SCHEMBL1876954 | 0.95 | GYS1 (0.37) | GYS1RXRANR1H2NR1H3FPR2 | |
| SCHEMBL1881813 | 0.95 | GYS1 (0.37) | GYS1RXRANR1H2NR1H3FPR2 | |
| SCHEMBL1882538 | 0.94 | GYS1 (0.40) | GYS1 | |
| SCHEMBL1882540 | 0.94 | GYS1 (0.40) | GYS1 | |
| SCHEMBL1883521 | 0.94 | GYS1 (0.40) | GYS1 | |
| SCHEMBL12635220 | 0.89 | NR1H2 (0.37) | RXRANR1H2NR1H3DGAT1 | |
| SCHEMBL1760374 | 0.82 | GYS1 (0.44) | GYS1RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | GYS1 2/4885RXRA 2824/4885NR1H2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.